Transfusion of Ipscs-Derived Leukocytes to Kill Cancer

Jiang Li,Ying Cui,Guodong Gao,Ti-Fei Yuan

doi:10.4236/jct.2010.11004

Abstract

Here we propose that the rejuvenation of leukocytes with iPSC technology in vitro and transfusion of cancer cellresistant white blood cells back to human body provide a prospective therapy for cancer patients.

Highlights

We propose that the rejuvenation of leukocytes with inducible pluripotent stem cell (iPSC) technology in vitro and transfusion of cancer cellresistant white blood cells back to human body provide a prospective therapy for cancer patients
60 years ago, Chester Southam injected healthy people and cancer patients with Hela cells, and found that healthy human beings are resistant to cancer cells, the ability of which was lost in cancer patients [1]
The important factors that lead to the loss of innate immunity during cancer progression include the failure of leukocytes in killing cancer cells and the fusion of cancer cell and leukocyte, which results in the metastasis of cancer cells [2]

Summary

Introduction

60 years ago, Chester Southam injected healthy people and cancer patients with Hela cells, and found that healthy human beings are resistant to cancer cells, the ability of which was lost in cancer patients [1]. A spontaneous cancer-resistant mice line was found, whose resistance is mediated by rapid infiltration of leukocytes and some other cells with innate immunity [3]. In these mice, the killing of injected cancer cells was completed by the migration of leukocytes to the cancer cells-injected site, the identification/recognition of specific antigens on the surface of cancer cells, as well as the release of cancer cell-killing substances, the first two steps of which do not exist in normal mice lines [3]. To restore the innate immunity, efforts must be made to re-activate the activity of white blood cells in patients with cancer, or to replace those “sick” leukocytes with healthy, young leukocytes engineered in vitro, the process of which can be completed with the recently emerged iPSC technology

IPSC Technology

The Hypothesis

Testing the Hypothesis and Clinical Significance